Leukaemia is a medical procedure that involves separating white blood cells from a sample of blood. The procedure is undergone to reduce the quantity of white blood cells in patients wuth hematological malignancies. Therefore, leukapheresis devices are the medical devices that are used to facilitate this procedure. The surge in demand for leukopaks in clinical research is one of the major factors fostering the growth of the market. Growth in the number of activities associated with blood donations coupled with growing innovations and advancements in technologies is another market growth determinant. Rising health awareness among individuals, growing approvals for processes of isolating white blood cells (WBC), and rising medical tourism are other important factors that will further generate lucrative market growth opportunities.
Market Dynamics
This global leukapheresis devices market report provides details of recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. For instance, In December 2021, ExThera Medical develops revolutionary medical devices that address unmet clinical needs in the treatment of bloodstream infections and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, entered into an exclusive distribution agreement in Japan for ExThera's Seraph 100 Microbind Affinity Blood Filter (Seraph 100). As per the agreement structure, ExThera Medical and Asahi Kasei Medical will collaborate to obtain regulatory approval for Seraph 100 for commercialization in Japan. The global leukapheresis devices market is expected to witness significant growth during the forecast period, owing to the increasing prevalence of leukemia. For instance, in June 2022, Terumo Blood is in blood component, therapeutic apheresis and cellular technologies and Cell Technologies, a medical technology company specializing in a portfolio of products, software, and services for blood component collection, therapeutic apheresis, and cellular technologies, announced it had signed a new collaborative agreement with GenCure, a subsidiary of BioBridge Global, to extend and unify cell and gene therapy manufacturing solutions.
Key features of the study:
Detailed Segmentation:
Table of Contents
About us and Sales Contact*Browse 36 market data tables and 33 figures on “Leukapheresis Devices Market ”- Global Forecast to 2030
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients